BioCryst Net Debt To E B I T D A from 2010 to 2025
| BCRX Stock | USD 7.80 0.27 3.35% |
Net Debt To EBITDA | First Reported 2010-12-31 | Previous Quarter (7.17) | Current Value (6.82) | Quarterly Volatility 2.75485774 |
Check BioCryst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioCryst Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1 M, Interest Expense of 103.4 M or Selling General Administrative of 279.4 M, as well as many indicators such as Price To Sales Ratio of 3.28, Dividend Yield of 0.0 or Days Sales Outstanding of 60.83. BioCryst financial statements analysis is a perfect complement when working with BioCryst Pharmaceuticals Valuation or Volatility modules.
BioCryst | Net Debt To E B I T D A |
Latest BioCryst Pharmaceuticals' Net Debt To E B I T D A Growth Pattern
Below is the plot of the Net Debt To E B I T D A of BioCryst Pharmaceuticals over the last few years. It is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). BioCryst Pharmaceuticals' Net Debt To EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioCryst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Debt To E B I T D A | 10 Years Trend |
|
Net Debt To E B I T D A |
| Timeline |
BioCryst Net Debt To E B I T D A Regression Statistics
| Arithmetic Mean | (1.51) | |
| Geometric Mean | 0.67 | |
| Coefficient Of Variation | (182.80) | |
| Mean Deviation | 2.17 | |
| Median | (0.27) | |
| Standard Deviation | 2.75 | |
| Sample Variance | 7.59 | |
| Range | 8.0544 | |
| R-Value | (0.74) | |
| Mean Square Error | 3.73 | |
| R-Squared | 0.54 | |
| Significance | 0 | |
| Slope | (0.43) | |
| Total Sum of Squares | 113.84 |
BioCryst Net Debt To E B I T D A History
About BioCryst Pharmaceuticals Financial Statements
BioCryst Pharmaceuticals investors use historical fundamental indicators, such as BioCryst Pharmaceuticals' Net Debt To E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioCryst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Debt To EBITDA | (7.17) | (6.82) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.